Selected Benefits of Pentoxifylline in Acute Ischemic Stroke Management: Consideration of Risk Factors
- DOI
- 10.2991/hsic-17.2017.68How to use a DOI?
- Keywords
- blood hyper viscosity; ischemic stroke; risk factor; pentoxifylline
- Abstract
The role of pentoxifylline in acute ischemic stroke lacks objective markers of its efficacy. In this study, we used blood viscosity as a specific marker to evaluate the efficacy of pentoxifylline. Objectives: This quasi-experimental study aimed to analyze pentoxifylline as an antihemorrheologic agent in acute ischemic stroke patients with certain risk factors, including age, smoking, hypertension, dyslipidemia, diabetes mellitus, and ischemic heart disease. Method: There were 22 acute ischemic stroke patients with blood hyper viscosity within 72 hours of onset who received pentoxifylline 1.200 mg/day for five days and continued with oral dose 400 mg twice daily for the next twenty-three days. All subjects received the standard treatment for acute ischemic stroke. The risk factors of stroke were recorded including smoking, hypertension, dyslipidemia, diabetes mellitus, and ischemic heart disease. Results: The median of baseline blood viscosity was 6.46 poise (5.20-9.73). The blood viscosity at the seventh and thirtieth day tend to decrease. The mean decrement blood viscosity level was statistically significant in smoking (p=0.009) and dyslipidemia (p=0.006) subjects. Clinical outcomes were assessed using the National Institutes of Health Stroke Scale (NIHSS), modified Rankin scale (mRS), and Barthel Index (BI). All subjects had good functional outcome and statistically significant for those who had diabetes mellitus and heart disease. Conclusion: Pentoxifylline is beneficial for acute ischemic stroke patients with risk factors of smoking, dyslipidemia, diabetes mellitus, and heart disease.
- Copyright
- © 2017, the Authors. Published by Atlantis Press.
- Open Access
- This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - CONF AU - Salim Harris AU - A Rasyid AU - Eny Nurhayati AU - J Prihartono PY - 2017/10 DA - 2017/10 TI - Selected Benefits of Pentoxifylline in Acute Ischemic Stroke Management: Consideration of Risk Factors BT - Proceedings of the Health Science International Conference (HSIC 2017) PB - Atlantis Press SP - 437 EP - 447 SN - 2468-5739 UR - https://doi.org/10.2991/hsic-17.2017.68 DO - 10.2991/hsic-17.2017.68 ID - Harris2017/10 ER -